Oxford Biomedica (LON:OXB) Shares Pass Below 200 Day Moving Average – Should You Sell?

Oxford Biomedica plc (LON:OXB)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 657.23 and traded as low as GBX 615. Oxford Biomedica shares last traded at GBX 630, with a volume of 7,015,429 shares.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of GBX 606.40.

Oxford Biomedica Stock Performance

The stock has a market cap of £757.62 million, a price-to-earnings ratio of -17.31 and a beta of 1.12. The company’s fifty day simple moving average is GBX 761.56 and its two-hundred day simple moving average is GBX 657.23. The company has a debt-to-equity ratio of 322.11, a current ratio of 1.89 and a quick ratio of 1.67.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.